I-Acute Lymphoblastic Leukemia(T-ALL)-08

UYesheng waseFujian uthe, "Ukuba bendisazi ngeCAR-T eLudaopei, ngendifike kwangoko."

NgoSeptemba ka-2017, uYesheng wavelisa irashes ebusweni, ethe yasasazeka ngokuthe ngcembe kwaye yadityaniswa kwiipatches. Ngomhla wama-28 kaFebruwari 2018, uvavanyo lomongo wamathambo luqinisekisile "i-acute T-cell lymphoblastic leukemia" emva kweekhosi ezininzi ze-chemotherapy, kunye nokuhlolwa okungahambi kakuhle okushiyekileyo. Onke amayeza aye amiswa ngoJuni ka-2019.

NgoMeyi ka-2021, u-Yesheng wabonisa abantu abaninzi kwingingqi yomlomo-pharyngeal kunye ne-lymph nodes zentamo. Ukuphononongwa kwakhona komongo wamathambo kuqinisekisile ukuphinda ngokupheleleyo kwe-leukemia. NgoMeyi 28, uYesheng watshintshelwa kwiSebe leSibini seHematology kwisibhedlele saseLudaopei ukuze amkelwe. Emva kovavanyo olubanzi, ukuxilongwa kwahlaziywa "kwi-acute leukemia (T / myeloid biphenotypic)."

Umjikelo omnye wechemotherapy awuzange ubangele ukuxolelwa kumongo wethambo. NgoJulayi 27, uYesheng wafumana iCD7 CAR-T cell infusion, elandelwa yichemotherapy edityaniswe neCD7 CAR-T cell therapy. Kwiintsuku ezilishumi elinesihlanu emva kokuxilwa, uvavanyo lomongo wethambo lubonise isifo esibi se-residual, kunye ne-grade 1 ye-cytokine release syndrome (CRS) reaction kunye ne-central nervous system reactions ezimbi.